UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.55 USD
+0.08 (5.44%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.53 -0.02 (-1.29%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Brokerage Reports
UNITY Biotechnology, Inc. [UBX]
Reports for Purchase
Showing records 21 - 40 ( 101 total )
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Beyond the Realms of VEGF; Initiating Buy, $10 PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Ph2b DME Trial to Begin in H2:23; Cash Runway Extended to Ph2b Readouts; Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term UBX1325 Senolytic Advancement - Progress For DME and wAMD; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
UBX1325''s Durability (BE)HOLDs Up to 48wk in DME Patients; Ph2b in H2:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Positive 48-Week Phase 2 BEHOLD Data Asserts UBX1325 Durability in DME; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Ph2 wAMD Failure Not What We Envisioned; Limited Read Thru to DME; PT to $5
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Interpreting Phase 2 ENVISION wAMD Readout in Context of DME Benefit -Transfer of Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Looking to UBX1325 Top-Line on 1H23 Near-Term Horizon; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
On-Track for 16wk & 24wk Ph2 wAMD Data at the End of March; Q4/FY22 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Considerations on Phase 2 wAMD ENVISION Data Anticipated 1Q23; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Investor Call Takeaways; Setting Expectations for 16wk/24wk wAMD Data in Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department